Cargando…

Effect of neoadjuvant therapy on breast cancer biomarker profile

BACKGROUND: Breast cancer clinical management requires the assessment of hormone receptors (estrogen (ER) and progesterone receptor (PR)), human epidermal growth factor receptor 2 (HER2) and cellular proliferation index Ki67, by immunohistochemistry (IHC), in order to choose and guide therapy accord...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rey-Vargas, Laura, Mejía-Henao, Juan Carlos, Sanabria-Salas, María Carolina, Serrano-Gomez, Silvia J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368678/ https://www.ncbi.nlm.nih.gov/pubmed/32682413 http://dx.doi.org/10.1186/s12885-020-07179-4

Ejemplares similares

Association of genetic ancestry with HER2, GRB7 AND estrogen receptor expression among Colombian women with breast cancer
por: Rey-Vargas, Laura, et al.
Publicado: (2022)

Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer
por: Huertas-Caro, Carlos A., et al.
Publicado: (2023)

Ancestry as a potential modifier of gene expression in breast tumors from Colombian women
por: Serrano-Gómez, Silvia J., et al.
Publicado: (2017)

Immune Lymphocyte Infiltrate and its Prognostic Value in Triple-Negative Breast Cancer
por: Huertas-Caro, Carlos Alexander, et al.
Publicado: (2022)

Impact of immunohistochemical profile changes following neoadjuvant therapy in the treatment of breast cancer
por: Candás, Gabriela, et al.
Publicado: (2021)

Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer
por: Nolen, Brian M, et al.
Publicado: (2008)

Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer
por: Juliachs, Mercè, et al.
Publicado: (2022)

Exploring the Potential Role of Circulating microRNAs as Biomarkers for Predicting Clinical Response to Neoadjuvant Therapy in Breast Cancer
por: Ruiz-Manriquez, Luis M., et al.
Publicado: (2023)

“To Anticipate”: Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers
por: Garutti, Mattia, et al.
Publicado: (2020)

Fecal Metabolic Profiling of Breast Cancer Patients during Neoadjuvant Chemotherapy Reveals Potential Biomarkers
por: Zidi, Oumaima, et al.
Publicado: (2021)

Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer
por: Cerbelli, Bruna, et al.
Publicado: (2020)

Neoadjuvant systemic therapy for breast cancer
por: Zaborowski, Alexandra M, et al.
Publicado: (2023)

Rapid response of breast cancer to neoadjuvant intramammary testosterone-anastrozole therapy: neoadjuvant hormone therapy in breast cancer
por: Glaser, Rebecca L., et al.
Publicado: (2014)

Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype
por: Orrù, Sandra, et al.
Publicado: (2023)

Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration
por: Zhou, Xingchen, et al.
Publicado: (2015)

Circulating regulatory T cells from breast cancer patients in response to neoadjuvant chemotherapy
por: Sánchez-Margalet, Víctor, et al.
Publicado: (2019)

On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer
por: Bownes, Richard J., et al.
Publicado: (2019)

Mammographic density as an image-based biomarker of therapy response in neoadjuvant-treated breast cancer patients
por: Skarping, Ida, et al.
Publicado: (2020)

Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer
por: Long, Mengping, et al.
Publicado: (2022)

Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy
por: Zarotti, Cristina, et al.
Publicado: (2022)

State of the art in neoadjuvant therapy of breast cancer
por: Minckwitz, Gunter von, et al.
Publicado: (2013)

Recent advances in neoadjuvant therapy for breast cancer
por: Potter, David A, et al.
Publicado: (2021)

Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers
por: Tan, Wenyong, et al.
Publicado: (2018)

Impact of residual disease biomarkers on the prognosis of HER2‐positive breast cancer following neoadjuvant therapy
por: Ma, Youzhao, et al.
Publicado: (2023)

Biomarker Dynamics and Long-Term Treatment Outcomes in Breast Cancer Patients with Residual Cancer Burden after Neoadjuvant Therapy
por: Holanek, Milos, et al.
Publicado: (2022)

Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer
por: Pennisi, Angela, et al.
Publicado: (2016)

Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer
por: Marcus, David M., et al.
Publicado: (2013)

Neoadjuvant Systemic Therapy for Breast Cancer: Factors Influencing Surgeons’ Referrals
por: Mamounas, Eleftherios, et al.
Publicado: (2016)

Pathologic Evaluation of Breast Cancer after Neoadjuvant Therapy
por: Park, Cheol Keun, et al.
Publicado: (2016)

Neoadjuvant Therapy in Nonmetastatic Breast Cancer in Kurdistan, Iraq
por: Namiq, Karez Sarbast, et al.
Publicado: (2023)

Effector Mechanisms of CD8+ HLA-DR+ T Cells in Breast Cancer Patients Who Respond to Neoadjuvant Chemotherapy
por: Osuna-Gómez, Rubén, et al.
Publicado: (2021)

Palbociclib in breast cancer neoadjuvant setting
por: Duarte, Sílvia Alexandra Cabral, et al.
Publicado: (2021)

Multidisciplinary Approach to Neoadjuvant Endocrine Therapy in Breast Cancer: A Comprehensive Review
por: Reinert, Tomás, et al.
Publicado: (2016)

Neoadjuvant Therapy in Operable Breast Cancer: Application to Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2013)

Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2020)

Biomarker expression in rectal cancer tissue before and after neoadjuvant therapy
por: Boogerd, Leonora SF, et al.
Publicado: (2018)

Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy
por: GHIMENTI, CHIARA, et al.
Publicado: (2013)

FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction
por: Liu, Shuo, et al.
Publicado: (2020)

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
por: da Silva, Jesse Lopes, et al.
Publicado: (2021)

Assesssment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer.
por: Gazet, J. C., et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_sf1tketnnauq61naqt28avslup